American College of Clinical Pharmacy
      Search      Cart
         

HIV PRN Focus Session -- Antiretroviral Care in 2019: Do the Numbers Matter?”

Sunday, October 27, 2019 from 4:00 PM to 5:30 PM EST at 2nd Floor: Murray Hill

Available for 1.50 hours of CPE credit
Activity Number: 0217-0000-19-213-L02-P
Activity Type: A Knowledge-Based Activity


Speakers
  • Edward E. Grace, Pharm.D., BCPS-AQ IDModerator: Edward E. Grace, Pharm.D., BCPS-AQ ID
    President, Sovereign Medical Consulting, LLC, Greenville, South Carolina

  • Moderator: David B. Cluck, Pharm.D.

Management of HIV in geriatrics
4:00 PM

Speakers
  • Melissa  Badowski, Pharm.D., BCPS, AAHIVPSpeaker: Melissa Badowski, Pharm.D., BCPS, AAHIVP
    Clinical Associate Professor, Section of Infectious Diseases Pharmacotherapy, University of Illinois at Chicago, College of Pharmacy; Illinois Department of Corrections HIV Telemedicine, Chicago, Illinois
      View Biography


Learning Objectives
1. Identify the most common challenges in the management of HIV in geriatric patients.
2. Evaluate the most common implications and solutions related to antiretroviral use in combination with other medications used in geriatric patients.
3. Evaluate the role of injectable antiretrovirals in the suppression of HIV in adult patients.
4. Define the role of 2-drug antiretroviral regimens in the management of HIV positive adult and geriatric patients.
Management of HIV in geriatrics - A Pro/Con Debate
4:40 PM

Speakers
  • Elizabeth M. Sherman, Pharm.D.Speaker: Elizabeth M. Sherman, Pharm.D.
    Associate Professor, Nova Southeastern University, College of Pharmacy, Fort Lauderdale, Florida; Division of Infectious Disease, Memorial Physician Group, Hollywood, Florida; Southeast AIDS Education and Training Center
      View Biography

  • Kimberly  Scarsi, Pharm.D., M.Sc.Speaker: Kimberly Scarsi, Pharm.D., M.Sc.
    Associate Professor, University of Nebraska Medical Center, College of Pharmacy, Omaha, Nebraska
      View Biography


Learning Objectives
1. Identify patients who would and would not benefit from treatment simplification (eg change to DTG/RPV;DTG/DRV/r; DTG/3TC).
2. Describe the role of 3TC/FTC in patients with the M184V mutation.
3. iii. Identify the long-term risks and benefits of N(Nt)RTI inclusion (ABC, TDF, TAF) in chronic suppressive ART regimens.